Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Between 2002-2005, probands from 300 US families with 4 or more cases of breast or ovarian cancer but with negative (wild-type) commercial genetic test results for BRCA1 and BRCA2 were screened by multiple DNA-based and RNA-based methods to detect genomic rearrangements in BRCA1 and BRCA2 and germline mutations of all classes in CHEK2, TP53, and PTEN.
|
16551709 |
2006 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 and BRCA2 mutations confer very high risks of breast and ovarian cancer. p53 and PTEN mutations lead to very high breast cancer risks associated with rare cancer syndromes.
|
17292821 |
2007 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PTEN mutations were not detected in 13 families at high risk of breast and/or ovarian cancer.
|
9399897 |
1997 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
One patient exhibited mutations both in PIK3CA and PTEN at discordant sites between endometrial and ovarian carcinomas, whereas the other 4 exhibited concordant mutations.
|
22635024 |
2012 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PTEN, a tumor suppressor gene, has been demonstrated to be able to reverse cisplatin-resistance in ovarian cancer cell line C13K.
|
24434152 |
2014 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Among several series of ovarian cancers, the frequency of loss of heterozygosity (LOH) of markers flanking and within PTEN, is approximately 30 to 50%, and the somatic intragenic PTEN mutation frequency is <10%.
|
11395387 |
2001 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In these cases, there is a high frequency of atypia in the endometriosis, and the endometriosis and the associated ovarian carcinoma may show identical PTEN mutations.
|
15381900 |
2004 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PTEN mutations were detected not only in the endometrioid type but also in the serous and mucinous types of ovarian cancer.
|
10629071 |
2000 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Alterations in beta-catenin and PTEN genes, as well as MSI, are frequent in low-stage ovarian carcinomas of endometrioid type that have a favorable prognosis.
|
15668893 |
2004 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that although PTEN mutations in ovarian cancer are rare, PTEN inhibition results in therapeutic sensitization.
|
26905328 |
2016 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations.
|
16793127 |
2006 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that PTEN/MMAC1 mutations are rare in ovarian cancers.
|
9625810 |
1998 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The frequencies of PTEN and TP53 were 0.21% and 0.53%, respectively, in the Southern Chinese patients with breast and/or ovarian cancers.
|
27157322 |
2016 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In two of the five cases of clinically synchronous cancers, identical or progressive PTEN mutations were found in both the endometrial and ovarian cancers, suggesting that the ovarian tumor is a metastasis from the endometrial primary.
|
9829719 |
1998 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
To explore the role of miR-200a combined with PTEN in the progression of ovarian carcinoma.
|
30024595 |
2018 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
PTEN, a tumor suppressor commonly mutated (50%) in endometrial carcinoma, is found mutated in endometrioid carcinoma of the ovary, but not in other forms of ovarian cancer.
|
11949955 |
2002 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Although many tumors presented a single lesion (28/93, of which 23 overexpressed PIK3CA, 1 overexpressed AKT and 4 had lost PTEN), many OC (35/93) presented multiple alterations within the PI3K pathway.
|
23408974 |
2013 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
<i>miR-216a</i> up-regulation is associated with cisplatin resistance in ovarian cancer and this effect is mediated by PTEN.
|
30061175 |
2018 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Subcutaneously transplanted nude mice, as a model of human ovarian cancer, were used to test the effects of PTEN and KRT10 on cisplatin resistance of ovarian cancer in vivo.
|
26125866 |
2015 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to determine whether upregulation of PTEN gene by transfection wild-type PTEN gene to ovarian cancer cells can inhibit growth and migration and to explore the potential for PTEN gene therapy of ovarian cancers.
|
18662848 |
2008 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Notably, the results of dual-luciferase reporter assays indicated that PTEN was a direct downstream target of miR-19b in OC.
|
29963131 |
2018 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Upregulation of microRNA-18b induces phosphatase and tensin homolog to accelerate the migration and invasion abilities of ovarian cancer.
|
29142608 |
2017 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
These findings indicate that deregulation of miRNAs is a recurrent event in human ovarian cancer and that miR-214 induces cell survival and cisplatin resistance primarily through targeting the PTEN/Akt pathway.
|
18199536 |
2008 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma.
|
31530568 |
2019 |